Smithkline Beecham Corporation

Glaxo Group Limited

Charanjit Bountra

Alan Naylor

Mervyn Thompson

David E Bays

Paul John Beswick

Ian B Campbell

Malcolm Stuart Nobbs

Harshad Kantilal Rami

John Beresford Davis

Neil Matthews

A method of treating conditions associated with pain and alleviating the symptoms associated therewith which comprises administering to a mammal, including man, a vanilloid VR-1 antagonist or a pharmaceutically acceptable derivative thereof and an NSAID or a pharmaceutically acceptable derivative thereof, wherein said VR-1 antagonist or said NSAID may optionally be administered as a sub-maximal amount.

Combinations of a vanilloid antagonist and an NSAID for the treatment of pain

The invention provides a pharmaceutical composition comprising a compound of formula (I)or a pharmaceutically acceptable salt, solvate, ester or salt or solvate of such ester, of a compound of formula (I) in which:

2,3-diaryl-pyrazolo[1,5-b]pyridazines derivatives, their preparation and their use as cyclooxygenase 2 (COX-2) inhibitors

The present invention relates to the use of sodium channel antagonists in the treatment of diseases mediated by, or exacerbated by, neuronal apoptosis, in particular sensory neuronal apoptosis.

Medical use

Use for GABA agonists for treating emesis

Growing community of inventors

Harlow, United Kingdom

Charanjit Bountra